Becton, Dickinson and Company (BD) reported strong Q3 fiscal 2026 results, surpassing analyst expectations with an EPS of $3.23 versus the estimated $3.14, and revenue of $4.98 billion beating the $4.89 billion forecast. Despite a year-over-year EPS decline from $3.68, BD showed robust financial health with a 44.6% increase in year-to-date free cash flow to $1.70 billion and a strong current ratio of 8.10. The company updated its full-year guidance, reflecting confidence in its focused MedTech strategy and growth platforms. CEO Tom Polen highlighted the benefits of BD's strategic focus and capital allocation for long-term value creation.
Among four Dividend Aristocrats highlighted a year ago, AbbVie and Becton Dickinson outperformed the market with strong dividend growth and solid financials, while Procter & Gamble and Brown-Forman lagged in price but maintained reliable dividend pay...
BD (Becton, Dickinson and Company) posted a 5.4% increase in Q3 revenue to $5.0 billion, driven by growth across its Medical Essentials, Connected Care, BioPharma Systems, and Interventional segments. Adjusted diluted EPS rose to $3.23, and cash from...
